Key Points
- Director Lorence Kim sold 56,000 Revolution Medicines shares at an average price of $203.24, generating approximately $11.38 million. The sale reduced his holdings by 76.62% to 17,090 shares.
- RVMD shares opened at $209.23, near their 52-week high of $224.31, despite the company reporting a quarterly loss of $3.06 per share—worse than analysts’ expected loss of $2.04.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $200.74; institutional investors own 94.34% of the company.
Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) Director Lorence Kim sold 56,000 shares of the company's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $203.24, for a total transaction of $11,381,440.00. Following the completion of the transaction, the director owned 17,090 shares in the company, valued at approximately $3,473,371.60. This trade represents a 76.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Revolution Medicines Trading Down 0.3%
Shares of RVMD opened at $209.23 on Thursday. Revolution Medicines, Inc. has a 1-year low of $38.49 and a 1-year high of $224.31. The company has a market capitalization of $44.85 billion, a P/E ratio of -23.72 and a beta of 1.40. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The firm's 50 day simple moving average is $195.72 and its 200 day simple moving average is $151.30.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same period last year, the firm earned ($1.31) EPS. Sell-side analysts forecast that Revolution Medicines, Inc. will post -8.84 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Revolution Medicines
Institutional investors have recently bought and sold shares of the stock. Meeder Advisory Services Inc. lifted its position in Revolution Medicines by 3.0% in the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company's stock valued at $401,000 after purchasing an additional 120 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Revolution Medicines by 1.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company's stock valued at $802,000 after buying an additional 125 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Revolution Medicines by 147.7% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 218 shares of the company's stock valued at $41,000 after buying an additional 130 shares during the period. Deutsche Bank AG boosted its position in Revolution Medicines by 0.4% during the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company's stock valued at $2,566,000 after buying an additional 130 shares during the period. Finally, Contravisory Investment Management Inc. bought a new stake in Revolution Medicines in the 2nd quarter worth $32,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
RVMD has been the topic of a number of research reports. Wolfe Research restated an "outperform" rating and set a $220.00 price target on shares of Revolution Medicines in a research report on Monday, August 10th. Oppenheimer increased their price objective on Revolution Medicines from $230.00 to $260.00 and gave the company an "outperform" rating in a research report on Thursday, August 27th. Mizuho raised their price objective on Revolution Medicines from $185.00 to $215.00 and gave the company an "outperform" rating in a report on Monday, July 6th. Evercore restated an "outperform" rating and issued a $320.00 target price on shares of Revolution Medicines in a research report on Thursday, August 27th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Revolution Medicines in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $200.74.
View Our Latest Stock Report on Revolution Medicines
About Revolution Medicines
(
Get Free Report)
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.
The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
